

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Single Technology Appraisal (STA)**

**Rivaroxaban for the prevention of stroke in atrial fibrillation**

**Matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Bayer HealthCare (rivaroxaban)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Heart</li> <li>• Afiya Trust</li> <li>• Anti Coagulation Europe (ACE)</li> <li>• Arrhythmia Alliance (AFA Affiliated)</li> <li>• Atrial Fibrillation Association (AFA)</li> <li>• Black Health Agency</li> <li>• Brain and Spine Foundation</li> <li>• British Cardiac Patients Association</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Different Strokes</li> <li>• Equalities National Council</li> <li>• Grown up Congenital Heart Patients</li> <li>• Heart Care Partnership (UK)</li> <li>•</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Neurological Alliance</li> <li>• Neurosupport</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> <li>• The Ashley Jolly SADS Trust (SADS UK)</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Specialist Association (ASA)</li> <li>• British Association for Nursing in Cardiac Care</li> <li>• British Association for Service to the</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• HealthCare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (aspirin, warfarin)</li> <li>• Alliance Pharmaceuticals (aspirin)</li> <li>• Arrow Generics (aspirin, warfarin)</li> <li>• Aspar Pharmaceuticals (aspirin)</li> <li>• Bayer (aspirin)</li> <li>• Boehringer Ingelheim (dabigatran etexilate)</li> <li>• Bristol Laboratories (aspirin)</li> <li>• Bristol-Myers Squibb &amp; Pfizer (apixaban)</li> <li>• Bristol-Myers Squibb (,aspirin warfarin sodium)</li> <li>• Dexcel-Pharma (aspirin)</li> </ul>

## Appendix B

Consultees	Commentators (no right to submit or appeal)
<p>Elderly</p> <ul style="list-style-type: none"> <li>• British Association of Stroke Physicians</li> <li>• British Cardiovascular Intervention Society (BCIS)</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis (BSHT)</li> <li>• British Society for Heart Failure</li> <li>• Clinical Leaders of Thrombosis (CLOT)</li> <li>• Heart Rhythm UK</li> <li>• National Heart Forum (UK) Primary Care Cardiovascular Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Vascular Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Berkshire East</li> <li>• Powys Teaching Health Board</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Focus Pharmaceuticals (aspirin)</li> <li>• Galpharm International (aspirin)</li> <li>• Generics UK (aspirin, warfarin)</li> <li>• Genus Pharmaceuticals (aspirin)</li> <li>• Goldshield Pharmaceuticals (warfarin)</li> <li>• Kent Pharmaceuticals (aspirin, warfarin)</li> <li>• Mylan UK (aspirin, warfarin)</li> <li>• Pinewood Healthcare (aspirin)</li> <li>• Reckitt Benckiser (aspirin)</li> <li>• Sandoz (aspirin, warfarin)</li> <li>• Sigma Pharmaceuticals (aspirin)</li> <li>• Sinclair Pharmaceuticals (aspirin)</li> <li>• Teva UK (aspirin, warfarin)</li> <li>• Thornton &amp; Ross (aspirin)</li> <li>• Winthrop Pharmaceuticals (warfarin, aspirin)</li> <li>• Wockhardt UK (aspirin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research [BCS affiliated]</li> <li>• Cardiovascular Diseases Specialist Library (CVDSL)</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Peripheral Vascular Diseases Group</li> <li>• Cochrane Stroke Group</li> <li>• CODA</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> <li>• Wellcome Trust - Cardiovascular Research Initiative</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• BMJ Evidence Centre</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p>

## Appendix B

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"><li>• National Clinical Guidelines Centre</li></ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"><li>• None</li></ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues

*PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS*

### Definitions:

National Institute for Health and Clinical Excellence  
Provisional matrix for the proposed technology appraisal of rivaroxaban for the prevention of stroke in atrial fibrillation  
Issue date: June 2011

### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.